Odonate Inc.
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is ba… Read more
Odonate Inc. (ODTCD) - Net Assets
Latest net assets as of : $- USD
Based on the latest financial reports, Odonate Inc. (ODTCD) has net assets worth $- USD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | -9.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.88 |
Odonate Inc. - Net Assets Trend (2019–2023)
This chart illustrates how Odonate Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Odonate Inc. (2019–2023)
The table below shows the annual net assets of Odonate Inc. from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $108.12 Million | +7.21% |
| 2022-12-31 | $100.85 Million | +70.17% |
| 2021-12-31 | $59.26 Million | -56.47% |
| 2020-12-31 | $136.15 Million | -16.12% |
| 2019-12-31 | $162.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Odonate Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14440000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $492.60 Million | 455.60% |
| Total Equity | $108.12 Million | 100.00% |
Odonate Inc. Competitors by Market Cap
The table below lists competitors of Odonate Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NYRSTAR
F:3NY1
|
$6.09 Million |
|
Lumos Diagnostics Holdings Limited
PINK:LDXHF
|
$6.09 Million |
|
Nusantara Voucher Distribution Tbk PT
JK:DIVA
|
$6.09 Million |
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
$6.09 Million |
|
Kurniamitra Duta Sentosa Tbk
JK:KMDS
|
$6.09 Million |
|
Aquaron Acquisition Corp. Common Stock
NASDAQ:AQU
|
$6.08 Million |
|
Chiangmai Frozen Foods Public Company Limited
BK:CM
|
$6.08 Million |
|
Resverlogix Corp.
PINK:RVXCF
|
$6.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Odonate Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 100,849,000 to 108,121,000, a change of 7,272,000 (7.2%).
- Net income of 7,325,000 contributed positively to equity growth.
- Share repurchases of 196,000 reduced equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.33 Million | +6.77% |
| Share Repurchases | $196.00K | -0.18% |
| Other Changes | $143.00K | +0.13% |
| Total Change | $- | 7.21% |
Book Value vs Market Value Analysis
This analysis compares Odonate Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.49x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.96x to 0.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $50639.63 | $150000.00 | x |
| 2020-12-31 | $282458.51 | $150000.00 | x |
| 2021-12-31 | $123209.98 | $150000.00 | x |
| 2023-12-31 | $303710.67 | $150000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Odonate Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.77%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (6.77%) is above the historical average (-45.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -68.90% | 0.00% | 0.00x | 1.16x | $-128.06 Million |
| 2020 | -92.81% | 0.00% | 0.00x | 1.23x | $-139.96 Million |
| 2021 | -115.27% | 0.00% | 0.00x | 1.33x | $-74.24 Million |
| 2022 | 42.58% | 0.00% | 0.00x | 1.03x | $32.86 Million |
| 2023 | 6.77% | 0.00% | 0.00x | 1.02x | $-3.49 Million |
Industry Comparison
This section compares Odonate Inc.'s net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Odonate Inc. (ODTCD) | $- | -68.90% | N/A | $6.09 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |